|Bid||52.90 x 800|
|Ask||52.98 x 900|
|Day's Range||52.35 - 54.80|
|52 Week Range||16.87 - 56.51|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.33|
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"). The complaint was filed in the U.S. District Court of Delaware.
Natera (NTRA) delivered earnings and revenue surprises of -21.05% and 17.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress.